Role of Janus kinase Inhibitors (JAKis) in Autoimmune Disorders: Review

Maged Naser, Mohamed M. Nasr, Lamia H. Shehata

Abstract


JAK inhibitors (JAKis) comprise a crucial therapeutic tool for managing patients with immune-mediated inflammatory disorders. Although often perceived as a uniform class of medications thought to be largely interchangeable, notable variances exist in their efficacy and safety profiles. This review explores the pharmacokinetic and pharmacodynamic distinctions among JAKis, underscoring their clinical significance based on the most recent evidence available. The article seeks to furnish rheumatologists, gastroenterologists, and dermatologists with pragmatic guidance in selecting the most suitable JAKi for each patient, given the void of evidence-based recommendations in this sphere, to enhance clinical outcomes. Due to its preferential mechanism on JAK1, metabolic processing in the intestine, and demonstrated lack of effect on male fertility, filgotinib may present an improved benefit/risk proportion in contrast to other less targeted JAKis.


Keywords


JAK Inhibitors, Pharmacokinetic, Pharmacodynamic, Efficacy, Safety.

Full Text:

PDF

References


- Sozzani, Silvano, et al. "Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review." Autoimmunity 47.5 (2014): 287-306.

- Schwartz, Daniella M., et al. "JAK inhibition as a therapeutic strategy for immune and inflammatory diseases." Nature reviews Drug discovery 16.12 (2017): 843-862.

- Tran, Florian, et al. "Patient reported outcomes in chronic inflammatory diseases: current state, limitations and perspectives." Frontiers in immunology 12 (2021): 614653.

- Lai, Yuping, and Chen Dong. "Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases." International immunology 28.4 (2016): 181-188.

- Schett, Georg, Iain B. McInnes, and Markus F. Neurath. "Reframing immune-mediated inflammatory diseases through signature cytokine hubs." New England Journal of Medicine 385.7 (2021): 628-639.

- Xin, Ping, et al. "The role of JAK/STAT signaling pathway and its inhibitors in diseases." International immunopharmacology 80 (2020): 106210.

- Wlassits, Rebekka, et al. "JAK-Inhibitors–A Story of Success and Adverse Events." Open Access Rheumatology: Research and Reviews (2024): 43-53.

- European Medicine Agency (2024d). Xeljanz®, summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf (Accessed July 15, 2024).

- Dhillon, Sohita, and Susan J. Keam. "Filgotinib: first approval." Drugs 80.18 (2020): 1987-1997.

- Turner, Mark D., et al. "Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease." Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1843.11 (2014): 2563-2582.

- Bagley, Christopher J., et al. "The structural and functional basis of cytokine receptor activation: lessons from the common β subunit of the granulocyte-macrophage colony-stimulating factor, Interleukin-3 (IL-3), and IL-5 receptors." Blood, The Journal of the American Society of Hematology 89.5 (1997): 1471-1482.

- Banerjee, Shubhasree, et al. "JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects." Drugs 77 (2017): 521-546.

- Choy, Ernest H. "Clinical significance of Janus Kinase inhibitor selectivity." Rheumatology 58.6 (2019): 953-962.

- O'Shea, John J., et al. "The JAK-STAT pathway: impact on human disease and therapeutic intervention." Annual review of medicine 66.1 (2015): 311-328.

- Lin, Chung MA, Faye AH Cooles, and John D. Isaacs. "Basic mechanisms of JAK inhibition." Mediterranean Journal of Rheumatology 31.Приложение 1 (2020): 100-104.

- Traves, Paqui G., et al. "JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib." Annals of the rheumatic diseases 80.7 (2021): 865-875.

- Cox, Luk, and Jan Cools. "JAK3 specific kinase inhibitors: when specificity is not enough." Chemistry & biology 18.3 (2011): 277-278.

- Haan, Claude, et al. "Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors." Chemistry & biology 18.3 (2011): 314-323.

- Harris, Clare, and JR Fraser Cummings. "JAK1 inhibition and inflammatory bowel disease." Rheumatology 60.Supplement_2 (2021): ii45-ii51.

- Park, Sung O., et al. "Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans." PloS one 8.3 (2013): e59675.

- Besancenot, Rodolphe, et al. "JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation." Blood, The Journal of the American Society of Hematology 124.13 (2014): 2104-2115.

- Park, Hyeong-Kyu, and Rexford S. Ahima. "Leptin signaling." F1000prime reports 6 (2014).

- Liu, Christine, et al. "A decade of JAK inhibitors: what have we learned and what may be the future?." Arthritis & Rheumatology 73.12 (2021): 2166-2178.

- European Medicine Agency (2024a). Jyseleca®, summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf (Accessed July 15, 2024).

-European Medicine Agency (2024b). Olumiant®, summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf (Accessed July 15, 2024).

-European Medicine Agency (2024c). Rinvoq®, summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf (Accessed July 15, 2024).

- Anderson, Kacey, et al. "Assessment of the effect of filgotinib on the pharmacokinetics of atorvastatin, pravastatin, and rosuvastatin in healthy adult participants." Clinical pharmacology in drug development 11.2 (2022): 235-245.

- Veeravalli, Vijayabhaskar, et al. "Critical assessment of pharmacokinetic drug–drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis treatment." Drug safety 43 (2020): 711-725.

- Sandborn, William J., et al. "Tofacitinib as induction and maintenance therapy for ulcerative colitis." New England Journal of Medicine 376.18 (2017): 1723-1736.

- Dhillon, Sohita, and Susan J. Keam. "Filgotinib: first approval." Drugs 80.18 (2020): 1987-1997.

- Feagan, Brian G., et al. "Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials." Alimentary pharmacology & therapeutics 54.11-12 (2021): 1442-1453.

- Sands, Bruce E., et al. "Lipid profiles in patients with ulcerative colitis receiving tofacitinib—implications for cardiovascular risk and patient management." Inflammatory bowel diseases 27.6 (2021): 797-808.

- Li, Na, et al. "Effect of JAK inhibitors on high-and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis." Clinical Rheumatology (2022): 1-12.

- Benucci, Maurizio, et al. "Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-i Study)." Journal of Clinical Medicine 13.6 (2024): 1821.

- Mach, François, et al. "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)." European heart journal 41.1 (2020): 111-188.

- Charles-Schoeman, C., R. Fleischmann, and J. Davignon. "1: CAS: 528: DC% 2BC2MXjtlSls7o% 3D: Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. vol. 67." Arthritis Rheumatol (2015): 616-625.

- Chen, Hongxin, et al. "Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis." Frontiers in Medicine 10 (2023): 1198988.

- Mohamed, Mohamed‐Eslam F., et al. "Effect of upadacitinib on the pharmacokinetics of rosuvastatin or atorvastatin in healthy subjects." Clinical Pharmacology in Drug Development 10.11 (2021): 1335-1344.

- Da Silva, Bruno César, et al. "Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis." World Journal of Gastroenterology: WJG 20.28 (2014): 9458.

- Reinisch, Walter, et al. "Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies." Annals of the rheumatic diseases 82.8 (2023): 1049-1058.

- Hu, Xiaoyi, et al. "The JAK/STAT signaling pathway: from bench to clinic." Signal transduction and targeted therapy 6.1 (2021): 402.

- Shawky, Ahmed M., et al. "A comprehensive overview of globally approved JAK inhibitors." Pharmaceutics 14.5 (2022): 1001.

- Xin, Ping, et al. "The role of JAK/STAT signaling pathway and its inhibitors in diseases." International immunopharmacology 80 (2020): 106210.

- Lee, Eun Bong, et al. "Tofacitinib versus methotrexate in rheumatoid arthritis." New England Journal of Medicine 370.25 (2014): 2377-2386.

- Van Vollenhoven, Ronald F., et al. "Tofacitinib or adalimumab versus placebo in rheumatoid arthritis." New England Journal of Medicine 367.6 (2012): 508-519.

- Van Der Heijde, Désirée, et al. "Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four–month phase III randomized radiographic study." Arthritis & Rheumatism 65.3 (2013): 559-570.

- Lee, Eun Bong, et al. "Tofacitinib versus methotrexate in rheumatoid arthritis." New England Journal of Medicine 370.25 (2014): 2377-2386.

- Keystone, Edward C., et al. "Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study." Annals of the rheumatic diseases 76.11 (2017): 1853-1861.

- Smolen, Josef S., et al. "Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study." Rheumatology 60.5 (2021): 2256-2266.

- Genovese, Mark C., et al. "Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial." The Lancet 391.10139 (2018): 2513-2524.

- Burmester, Gerd R., et al. "Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial." The Lancet 391.10139 (2018): 2503-2512.

- Strand, Vibeke, et al. "Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE." Rheumatology 60.12 (2021): 5583-5594.

- van Vollenhoven, Ronald, et al. "Efficacy and safety of upadacitinib monotherapy in methotrexate‐naive patients with moderately‐to‐severely active rheumatoid arthritis (SELECT‐EARLY): a multicenter, multi‐country, randomized, double‐blind, active comparator–controlled trial." Arthritis & Rheumatology 72.10 (2020): 1607-1620.

- Genovese, Mark C., et al. "Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial." Jama 322.4 (2019): 315-325.

- Ytterberg, Steven R., et al. "Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis." New England Journal of Medicine 386.4 (2022): 316-326.

- Strand, Vibeke, et al. "Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond." RMD open 5.1 (2019): e000808.

- Smolen, Josef S., et al. "Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study." The Lancet 393.10188 (2019): 2303-2311.

- Orbai, Ana-Maria, et al. "Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)." Rheumatology 59.7 (2020): 1495-1504.

- Deodhar, Atul, et al. "Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study." Annals of the rheumatic diseases 80.8 (2021): 1004-1013.

- van der Heijde, Désirée, et al. "Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial." The Lancet 394.10214 (2019): 2108-2117.

- van der Heijde, Désirée, et al. "Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial." The Lancet 392.10162 (2018): 2378-2387.

- Sandborn, William J., et al. "Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status." Clinical Gastroenterology and Hepatology 20.3 (2022): 591-601.

- Rogler, Gerhard. "Efficacy of JAK inhibitors in Crohn’s disease." Journal of Crohn's and Colitis 14.Supplement_2 (2020): S746-S754.

- Sandborn, William J., et al. "Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease." Gastroenterology 158.8 (2020): 2123-2138.

- Vermeire, Séverine, et al. "Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial." The Lancet 389.10066 (2017): 266-275.

- Reich, Kristian, et al. "Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial." JAMA dermatology 156.12 (2020): 1333-1343.

- Guttman-Yassky, Emma, et al. "Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial." Journal of Allergy and Clinical Immunology 145.3 (2020): 877-884.

- Kim, Brian S., et al. "Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream." Journal of Allergy and Clinical Immunology 145.2 (2020): 572-582.

- Nakagawa, Hidemi, et al. "Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study." Journal of the American Academy of Dermatology 82.4 (2020): 823-831.

- Gladman, Dafna, et al. "Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors." New England Journal of Medicine 377.16 (2017): 1525-1536.

- Mease, Philip, et al. "Tofacitinib or adalimumab versus placebo for psoriatic arthritis." New England Journal of Medicine 377.16 (2017): 1537-1550.

- Papp, Kim, et al. "Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis." New England Journal of Medicine 379.14 (2018): 1313-1321.

- Squibb, Bristol Myers. "Bristol Myers Squibb Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Adult Patients with Moderate to Severe Ulcerative Colitis. Corporate/Financial News 2020." 2021,

- Kvist-Hansen, Amanda, Peter Riis Hansen, and Lone Skov. "Systemic treatment of psoriasis with JAK inhibitors: a review." Dermatology and therapy 10 (2020): 29-42.

- Phan, K., and D. F. Sebaratnam. "JAK inhibitors for alopecia areata: a systematic review and meta‐analysis." Journal of the European Academy of Dermatology and Venereology 33.5 (2019): 850-856.

- Furumoto, Yasuko, et al. "Tofacitinib ameliorates murine lupus and its associated vascular dysfunction." Arthritis & Rheumatology 69.1 (2017): 148-160.

- Dong, J., et al. "Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice." Lupus 16.2 (2007): 101-109.

- Wang, S., et al. "Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice." Lupus 19.10 (2010): 1171-1180.

- Ripoll, Èlia, et al. "JAK3-STAT pathway blocking benefits in experimental lupus nephritis." Arthritis research & therapy 18 (2016): 1-12.

- Chan, Emilie S., Leal C. Herlitz, and Jabbari Ali. "Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model." The Journal of investigative dermatology 135.9 (2015): 2338-2339.

- Petri, Michelle, et al. "Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)." The Lancet 401.10381 (2023): 1011-1019.

- Chan, Emilie S., Leal C. Herlitz, and Jabbari Ali. "Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model." The Journal of investigative dermatology 135.9 (2015): 2338-2339.

- Wenzel, Joerg, et al. "JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus." Journal of Investigative Dermatology 136.6 (2016): 1281-1283.

- Baker, Matthew, et al. "Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy." RMD open 6.3 (2020): e001490.

- Werth, Victoria P., et al. "Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study." Rheumatology 61.6 (2022): 2413-2423.

- Burke, James R., et al. "Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain." Science translational medicine 11.502 (2019): eaaw1736.

- Morand, Eric, et al. "Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double‐blind, placebo‐controlled trial." Arthritis & Rheumatology 75.2 (2023): 242-252.

- Carstens, P-O., and J. Schmidt. "Diagnosis, pathogenesis and treatment of myositis: recent advances." Clinical & Experimental Immunology 175.3 (2014): 349-358.

- Paudyal, Aliza, et al. "JAK‐inhibitors for dermatomyositis: a concise literature review." Dermatologic Therapy 34.3 (2021): e14939.

- Shneyderman, Matthew, et al. "Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series." Rheumatology 60.11 (2021): e387-e388.

- Wendel, Sarah, et al. "Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib–A report of two cases." Journal of autoimmunity 100 (2019): 131-136.

- Selva-O’Callaghan, A., et al. "Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease." Current Treatment Options in Rheumatology (2021): 1-15.

- Kurasawa, Kazuhiro, et al. "Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis." Rheumatology 57.12 (2018): 2114-2119.

- Kato, Manami, et al. "Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis." JCR: Journal of Clinical Rheumatology 27.8S (2021): S574-S577.

- Chen, Zhiwei, Xiaodong Wang, and Shuang Ye. "Tofacitinib in amyopathic dermatomyositis–associated interstitial lung disease." New England Journal of Medicine 381.3 (2019): 291-293.

- Takatani, Ayuko, et al. "Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis." Clinical immunology (Orlando, Fla.) 215 (2020): 108451.

- Ohmura, Shin-ichiro, Toru Yamabe, and Taio Naniwa. "Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies." Modern rheumatology case reports 5.1 (2021): 76-81.

- Marchiset, Antoine, et al. "High-emergency lung transplantation for interstitial lung disease associated with anti-MDA5 dermatomyositis: a case report." Transplantation Proceedings. Vol. 53. No. 8. Elsevier, 2021.

- Shirai, Tsuyoshi, et al. "Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associated protein-5 antibody-positive dermatomyositis." Clin Exp Rheumatol 41.2 (2023): 291-300.

- Paik, Julie J., et al. "Study of tofacitinib in refractory dermatomyositis: an open‐label pilot study of ten patients." Arthritis & Rheumatology 73.5 (2021): 858-865.

- Zhao, Qian, et al. "Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open-label study." Journal of the American Academy of Dermatology 87.6 (2022): 1374-1376.

- Delvino, Paolo, et al. "Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis." Rheumatology 59.12 (2020): e125-e127.

- Allenbach, Yves, et al. "Reply: a child with severe juvenile dermatomyositis treated with ruxolitinib." Brain 141.11 (2018): e81-e81.

- Aeschlimann, Florence A., et al. "A child with severe juvenile dermatomyositis treated with ruxolitinib." Brain 141.11 (2018): e80-e80.

- Heinen, André, et al. "Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?." Rheumatology 60.4 (2021): e136-e138.

- Hornung, Thorsten, et al. "Remission of recalcitrant dermatomyositis treated with ruxolitinib." New England Journal of Medicine 371.26 (2014): 2537-2538.

- Bellamri, Nessrine, et al. "Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis." International Immunopharmacology 116 (2023): 109723.

- Salem, Joe-Elie, et al. "Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis." Cancer Discovery 13.5 (2023): 1100-1115.

- Bellamri, Nessrine, et al. "Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis." International Immunopharmacology 116 (2023): 109723.

- Aung, Wah, et al. "Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma." Journal of dermatological science 101.3 (2021): 174-184.

- Tang, Liu-Ya, et al. "Transforming growth factor-β (TGF-β) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway." Journal of Biological Chemistry 292.10 (2017): 4302-4312.

- Skaug, Brian, and Shervin Assassi. "Type I interferon dysregulation in Systemic Sclerosis." Cytokine 132 (2020): 154635.

- Brkic, Zana, et al. "The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis." Annals of the rheumatic diseases 75.8 (2016): 1567-1573.

- Muangchan, Chayawee, and Janet E. Pope. "Interleukin 6 in systemic sclerosis and potential implications for targeted therapy." The Journal of rheumatology 39.6 (2012): 1120-1124.

- Denton, Christopher P., et al. "Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis." Annals of the Rheumatic Diseases 77.9 (2018): 1362-1371.

- Khanna, Dinesh, et al. "Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet Respiratory Medicine 8.10 (2020): 963-974.

- Wang, Wenxia, et al. "The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib." Journal of Scleroderma and Related Disorders 5.1 (2020): 40-50.

- Moriana, Clothilde, et al. "JAK inhibitors and systemic sclerosis: a systematic review of the literature." Autoimmunity reviews 21.10 (2022): 103168.

- Nallapati, Anshula, Fredrick M. Wigley, and Julie J. Paik. "Improvement of salt and pepper skin changes in diffuse scleroderma after treatment with tofacitinib." Clinical and experimental rheumatology 40.10 (2022): 2008.

- Deverapalli, S. C., and D. Rosmarin. "The use of JAK inhibitors in the treatment of progressive systemic sclerosis." Journal of the European Academy of Dermatology & Venereology 32.8 (2018).

- You, Hanxiao, et al. "Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis." Rheumatology 60.5 (2021): 2472-2477.

- Karalilova, Rositsa Valerieva, et al. "Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound." Rheumatology International 41.10 (2021): 1743-1753.

- Hou, Zhanying, et al. "JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis." Frontiers in Medicine 9 (2022): 859330.

- Fiorentini, Elisa, et al. "Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data." Life 12.12 (2022): 2101.

- Both, Tim, et al. "Reviewing primary Sjögren's syndrome: beyond the dryness-From pathophysiology to diagnosis and treatment." International journal of medical sciences 14.3 (2017): 191.

- Taylor, Kimberly E., et al. "Genome‐wide association analysis reveals genetic heterogeneity of Sjögren's syndrome according to ancestry." Arthritis & Rheumatology 69.6 (2017): 1294-1305.

- Teos, Leyla Y., and Ilias Alevizos. "Genetics of Sjögren's syndrome." Clinical Immunology 182 (2017): 41-47.

- El Jammal, Thomas, et al. "Les inhibiteurs de JAK: perspectives pour la médecine interne." La Revue de Médecine Interne 40.12 (2019): 816-825.

- Aota, Keiko, et al. "Inhibition of JAK-STAT signaling by baricitinib reduces interferon-γ-induced CXCL10 production in human salivary gland ductal cells." Inflammation 44 (2021): 206-216.

- Wallace, Daniel J., et al. "Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial." The Lancet 392.10143 (2018): 222-231.

- Bai, Wei, et al. "Pilot study of baricitinib for active Sjogren’s syndrome." Annals of the Rheumatic Diseases 81.7 (2022): 1050-1052.

- Price, Elizabeth, et al. "Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study." Rheumatology 61.12 (2022): 4797-4808.

- Zhou, Tong, et al. "Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature." Scientific reports 7.1 (2017): 4237.

- Damsky, William, et al. "Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis." New England Journal of Medicine 379.26 (2018): 2540-2546.

- Rotenberg, Cécile, et al. "Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia." European Respiratory Journal 52.6 (2018).

- Wei, Jenny J., et al. "Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera." JAAD Case Reports 5.4 (2019): 360-361.

- Levraut, Michael, et al. "Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib." Annals of the Rheumatic Diseases 78.11 (2019): 1606-1607.

- Herman, Jerome H., et al. "Cytokine modulation of chondrocyte proteinase release." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 27.1 (1984): 79-91.

- Saklatvala, J. "Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage." Nature 322.6079 (1986): 547-549. [140]- Padoan, Roberto, et al. "Biologic therapy in relapsing polychondritis: navigating between options." Expert Opinion on Biological Therapy 22.5 (2022): 661-671.

- Padoan, Roberto, et al. "Biologic therapy in relapsing polychondritis: navigating between options." Expert Opinion on Biological Therapy 22.5 (2022): 661-671.

- Meshkov, Alexey D., et al. "Tofacitinib in steroid-dependent relapsing polychondritis." Annals of the Rheumatic Diseases 78.7 (2019): e72-e72.

- Al-Mousawi, Alia Z., et al. "Reviewing the pathophysiology behind the advances in the management of giant cell arteritis." Ophthalmology and therapy 8 (2019): 177-193.

- Prigent, Kevin, et al. "JAK inhibitor effectiveness in giant-cell arteritis with large-vessel involvement assessed by 18F-FDG PET-CT." Clinical Nuclear Medicine 47.3 (2022): 234-235.

- Weyand, Cornelia M., and Jörg J. Goronzy. "Medium-and large-vessel vasculitis." New England Journal of Medicine 349.2 (2003): 160-169.

- Seko, Y., et al. "Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis." The Journal of clinical investigation 93.2 (1994): 750-758.

- Kong, Xiufang, et al. "Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study." Annals of the Rheumatic Diseases 81.1 (2022): 117-123.

- Hamedi, M., et al. "Differential expression of suppressor of cytokine signalling proteins in Behcet's disease." Scandinavian Journal of Immunology 80.5 (2014): 369-376.

- Liu, Jinjing, et al. "A pilot study of tofacitinib for refractory Behçet’s syndrome." Annals of the rheumatic diseases 79.11 (2020): 1517-1520.

- Liu, Yun, et al. "Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study." Annals of the Rheumatic Diseases 80.12 (2021): 1631-1633.

- Rimar, Doron, et al. "Response to:‘Tofacitinib for the treatment of polyarteritis nodosa: a literature review’. Correspondence on ‘Tofacitinib for polyarteritis nodosa: a tailored therapy’by Rimar et al." Annals of the Rheumatic Diseases 81.10 (2022): e205-e205.

- Zhu, Kai-Jun, Pei-Dan Yang, and Qiang Xu. "Tofacitinib treatment of refractory cutaneous leukocytoclastic vasculitis: a case report." Frontiers in Immunology 12 (2021): 695768.

- Ruperto, Nicolino, et al. "Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial." The Lancet 398.10315 (2021): 1984-1996.

- Bourbon, Estelle, et al. "Therapeutic options in VEXAS syndrome: insights from a retrospective series." Blood, The Journal of the American Society of Hematology 137.26 (2021): 3682-3684.

- Álvarez-Reguera, Carmen, et al. "Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review." Therapeutic Advances in Musculoskeletal Disease 14 (2022): 1759720X221093211.

- Maschalidi, Sophia, et al. "Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice." Blood, The Journal of the American Society of Hematology 128.1 (2016): 60-71.

- Carter, Stuart J., Rachel S. Tattersall, and Athimalaipet V. Ramanan. "Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment." Rheumatology 58.1 (2019): 5-17.

- Meng, Guang-Qiang, et al. "Establishment of Secondary HLH Mouse Model and Effect of Ruxolitinib on Disease Manifestations of Model Mide." Zhongguo shi yan xue ye xue za zhi 28.4 (2020): 1376-1380.

- Ahmed, Asra, et al. "Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial." The Lancet Haematology 6.12 (2019): e630-e637.

- Wang, Jingshi, et al. "Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis." Haematologica 105.5 (2020): e210.

- Wang, Jingshi, et al. "Ruxolitinib‐combined doxorubicin‐etoposide‐methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single‐arm, multicentre, phase 2 trial." British journal of haematology 193.4 (2021): 761-768.




DOI: http://dx.doi.org/10.52155/ijpsat.v48.1.6842

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Maged Naser

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.